Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023 22:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis logo.png
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
November 29, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
FDA has set a PDUFA target action date of July 07, 2024Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United StatessNDA supported by positive efficacy and...
Arcutis logo.png
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
November 03, 2023 07:30 ET | Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2023, and provided a business update.
Arcutis logo.png
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023 16:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis logo.png
Arcutis to Report Third Quarter 2023 Financial Results
October 25, 2023 16:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis will host a conference call and webcast at 8:30 a.m. ET on 11/3/2023 to report its third quarter financial results and provide a business update.
Arcutis logo.png
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
October 20, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
New individual patient response data showed nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in PASI
Arcutis logo.png
Arcutis Announces Pricing of $100 Million Public Offering
October 19, 2023 23:45 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing...
Arcutis logo.png
Arcutis Announces Proposed Public Offering
October 19, 2023 16:04 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage company focused on developing meaningful innovations...
Arcutis logo.png
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
October 13, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.
Arcutis logo.png
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
October 06, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced the FDA has approved an sNDA to expand the indication of ZORYVE (roflumilast) cream 0.3%.